What’s the difference between Ozempic and Wegovy? It can be confusing because, unlike most prescription drugs with different names, the active ingredient in both of them is actually the same: semaglutide [1, 2]. Semaglutide is a long-lived version of our body’s natural hunger-reducing GLP-1 hormone that lasts a week instead of a few minutes [3].
So why two names for the same drug? In the US, it’s because of how the Food and Drug Administration (FDA) tests and approves drugs [4]. If a pharmaceutical company wants to get their shiny new drug approved for sale, it has to apply for one or more specific use cases, with a dosage range and formulation for each. This typically requires a years-long process of animal and human clinical trials to confirm the shiny new drug is safe and effective for said purpose. If all goes well, the drug is now officially “labeled” by the FDA, so doctors can prescribe it and insurance companies can start covering it.
For example, Ozempic was created by a Danish pharmaceutical company called Novo Nordisk for type 2 diabetes because it lowers blood sugar, which it got FDA approval for in 2017 [5]. One of the side effects they noticed during the original clinical trials was that participants taking semaglutide reported feeling less hungry overall, and many of them ended up losing a significant amount of weight compared to those who didn’t [1].
Ozempic was approved for type 2 diabetes, where the pancreas helps keep blood sugar in check.
But FDA approvals are a strict process, and at that point increasing the approved dosage for weight-loss purposes would require a whole new round of expensive clinical trials. And since Novo Nordisk had already been trying to make more effective weight-loss drugs, they quickly began new trials in 2018 [6] to market semaglutide as a treatment for obesity and related health problems. Fast-forward just three short and totally normal years later, and Wegovy was approved for weight loss in 2021 [7].
Wegovy was approved for weight management, and later to lower heart risk in some adults.
Wegovy, like Ozempic, is semaglutide, but with a higher dose on a different ramp-up schedule [1, 2]. And since Wegovy was hard to come by and relied on the same active ingredient, many doctors simply started prescribing Ozempic off-label. Combine that with the booming demand for any form of semaglutide across the country and you’ve got a recipe for severe shortages for BOTH drugs that wouldn’t be declared over until 2025 [8]. (But that’s a story for another post!)
Each label has its own dose range and ramp-up schedule.
So in a nutshell: same molecule, different products for different problems. Even if two prescription medications have the same active drug, the timing, amount, and way that drug is taken mean the two aren’t interchangeable. And finding out which one is (or isn’t) right for you is, as always, a question for you and your doctor.
Sources
- Ozempic prescribing information. Novo Nordisk, revised 2026. https://www.novo-pi.com/ozempic.pdf
- Wegovy prescribing information. Novo Nordisk, revised 2026. https://www.novo-pi.com/wegovy.pdf
- Lau J, et al. Discovery of the once-weekly GLP-1 analogue semaglutide. J Med Chem. 2015;58:7370–7380. https://doi.org/10.1021/acs.jmedchem.5b00726
- Development & Approval Process: Drugs. U.S. Food and Drug Administration. https://www.fda.gov/drugs/development-approval-process-drugs
- Ozempic approved for type 2 diabetes, December 2017. Lasker Foundation, 2024 Lasker~DeBakey Clinical Medical Research Award. https://laskerfoundation.org/winners/glp-1-based-therapy-for-obesity/
- Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1; enrolled June to November 2018). N Engl J Med. 2021;384:989–1002. https://doi.org/10.1056/NEJMoa2032183
- Wegovy approved for chronic weight management, June 2021. FDA Office of Women’s Health e-Update, June 2021. https://www.fda.gov/consumers/june-2021-office-womens-health-e-update
- FDA declares the semaglutide shortage resolved. HCPLive, February 21, 2025. https://www.hcplive.com/view/fda-announces-end-to-shortage-of-semaglutide-products-ozempic-wegovy-
Nich Osborn